Laterza Barbara, Kusamura Shigeki, Baratti Dario, Oliva Grazia Daniela, Deraco Marcello
Department of Surgery, National Cancer Institute, Milan, Italy.
In Vivo. 2009 Jan-Feb;23(1):187-90.
Prognosis of peritoneal mesothelioma (PM) treated by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is closely related to the completeness of the surgical cytoreduction. The reliability of explorative laparoscopy (EL) in selecting patients with PM amenable to optimal combined treatment has never been specifically assessed.
Thirty-three patients with PM underwent EL before CRS and closed-abdomen HIPEC with cisplatin and doxorubicin. EL effectiveness in predicting complete cytoreduction (residual tumour nodules < or = 2.5 mm) was analyzed.
At EL, peritoneal involvement was considered amenable to complete CRS in 30 out of 33 patients (91%). In this group, cytoreduction was complete in 29 patients and incomplete in one. Three patients were judged not amenable to complete CRS and subsequently were not able to undergo complete cytoreduction.
EL findings can integrate clinical and radiological information in the selection process of patients with PM for combined treatment.
经细胞减灭术(CRS)和腹腔内热灌注化疗(HIPEC)治疗的腹膜间皮瘤(PM)的预后与手术细胞减灭的彻底性密切相关。探索性腹腔镜检查(EL)在选择适合最佳联合治疗的PM患者中的可靠性从未得到专门评估。
33例PM患者在CRS和使用顺铂及阿霉素的闭合腹腔HIPEC之前接受了EL。分析了EL在预测完全细胞减灭(残留肿瘤结节≤2.5mm)方面的有效性。
在EL时,33例患者中有30例(91%)的腹膜受累被认为适合进行完全CRS。在该组中,29例患者的细胞减灭是完全的,1例不完全。3例患者被判定不适合进行完全CRS,随后无法进行完全细胞减灭。
EL结果可在PM患者联合治疗的选择过程中整合临床和放射学信息。